8.61
-0.71(-7.62%)
Currency In USD
| Previous Close | 9.32 |
| Open | 9.21 |
| Day High | 9.38 |
| Day Low | 8.52 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 144,760 |
| Average Volume | 80,403 |
| Market Cap | 52.96M |
| PE | -0.68 |
| EPS | -12.66 |
| Moving Average 50 Days | 10.1 |
| Moving Average 200 Days | 11.01 |
| Change | -0.71 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $23.19 as of October 30, 2025 at a share price of $8.61. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $328 as of October 30, 2025 at a share price of $8.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
GlobeNewswire Inc.
Oct 16, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
GlobeNewswire Inc.
Oct 14, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 12:30 PM GMT
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical st